Estimated continuous annual BCSM rates and hazard ratio of BCSM.

<p>A, B & C show estimated continuous annual BCSM rates. The solid line represents patients in cohort 1; the dashed line represents patients in cohort 2.D, E & F show differences of BCSM between patients in the two cohorts. Patients in C1 as reference, the absolute number of decreased BCSM rate (C2 minus C1).G, H & I show hazard ratio of BCSM (Cohort 1 versus cohort 2). Light grey shadows represent 95% CI of survival. HRs with 95% CIs were estimated from the flexible parametric survival models. Curves cut off at 0.5 yrs from diagnosis because of sparse data. Total population: A, D & G; ER negative: B, E & H; ER positive: C, F & I. Notes: Rates were reported per 1000 persons per year; y-axis scales were different in different analyses.</p

Annual BCSM rates and hazard ratio of BCSM in the total population and different subgroups.

<p>Annual BCSM rates and hazard ratio of BCSM in the total population and different subgroups.</p

Estimated continuous annual BCSM rates and hazard ratio of BCSM according to age and ER status.

Estimated continuous annual BCSM rates and hazard ratio of BCSM according to age and ER status.</p

Patient characteristics.

<p>Patient characteristics.</p

Estimated continuous annual BCSM rates and hazard ratio of BCSM in certain subpopulations.

<p>(A) Patients were age<40 with ER negative and node positive diseases. (B) Patients were age≥60 with ER positive and node negative diseases.</p

Filtration process.

<p>We identified 228209 female patients (20 and 84 yrs) diagnosed stages I to III unilateral invasive breast cancer between January 1, 1990, and December 31, 2005, through Surveillance, Epidemiology, and End Results (SEER) Program (<a href="http://www.seer.cancer.gov/" target="_blank">www.seer.cancer.gov</a>) SEER*Stat Database: Incidence—SEER 18 Regs Research Data released April 2015, based on the November 2014 submission.</p

Diffuse positive stain for ER in IMPC component.

<p>Diffuse positive stain for ER in IMPC component.</p

Compared with the cumulative disease free survival rate curve of invasive micropapillary carcinoma (IMPC) and invasive ductal carcinoma (IDC) (<i>P</i> = .606).

<p>Compared with the cumulative disease free survival rate curve of invasive micropapillary carcinoma (IMPC) and invasive ductal carcinoma (IDC) (<i>P</i> = .606).</p

The pathologic characteristics between IMPC patients with and without recurrence.

1<p><b>IMPC:</b> invasive micropapillary carcinoma;</p>2<p><b>LVI:</b> Lymphovascular invasion;</p>3<p><b>G1:</b> Grade 1;</p>4<p><b>G2</b>: Grade 2;</p>5<p><b>G3:</b> Grade 3.</p><p>The pathologic characteristics between IMPC patients with and without recurrence.</p

Positive stain for EMA antigen on the peripheral cell membranes is suggestive of “inside-out” morphology.

<p>Positive stain for EMA antigen on the peripheral cell membranes is suggestive of “inside-out” morphology.</p